Last Week Cidara Therapeutics, Inc. (NASDAQ:CDTX) Ratings

May 3, 2018 - By Alex Paulin

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Corporate Logo

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Ratings Coverage

Total analysts of 2 have positions in Cidara Therapeutics (NASDAQ:CDTX) as follows: 2 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. The firm has $16 highest while $15.0 is the lowest target price. The average target $15.50 is 260.47% above the last ($4.3) price. Since November 8, 2017 according to StockzIntelligence Inc Cidara Therapeutics has 3 analyst reports. On Thursday, November 9 H.C. Wainwright maintained Cidara Therapeutics, Inc. (NASDAQ:CDTX) rating. H.C. Wainwright has “Buy” rating and $16 target. On Tuesday, February 27 the rating was maintained by Cantor Fitzgerald with “Buy”. The stock rating was maintained by Cantor Fitzgerald with “Buy” on Wednesday, November 8. Listed here are Cidara Therapeutics, Inc. (NASDAQ:CDTX) PTs and latest ratings.

27/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $15.0 Maintain
09/11/2017 Broker: H.C. Wainwright Rating: Buy Old Target: $14 New Target: $16 Maintain
08/11/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $15.0 Maintain

At traded at $4.3 lastly.Since May 3, 2017 it’s 44.16% down thus downtrending. CDTX underperformed by 55.71% the S&P 500.

Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of various diseases.The firm is valued at $92.00 million. The Company’s lead product candidate is CD101 IV, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious, invasive fungal infections.Last it reported negative earnings. The firm also develops CD201, a novel bispecific antimicrobial immunotherapy for the treatment of multidrug-resistant gram-negative bacterial infections, including those caused by pathogens harboring the mcr-1 plasmid.

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.